Callan Family Office’s Zoetis ZTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$900K Sell
12,528
-9,157
-42% -$862K 0.02% 625
2026
Q1
$2.56M Buy
21,685
+154
+0.7% +$19K 0.06% 296
2025
Q4
$2.71M Buy
21,531
+8,260
+62% +$1.08M 0.06% 287
2025
Q3
$1.94M Sell
13,271
-2,446
-16% -$370K 0.06% 269
2025
Q2
$2.45M Buy
15,717
+9,170
+140% +$1.45M 0.08% 246
2025
Q1
$1.08M Sell
6,547
-370
-5% -$61.5K 0.08% 207
2024
Q4
$1.13M Buy
+6,917
New +$1.24M 0.07% 228

Other funds holding ZTS

Callan Family Office's ZTS Position: Q2 2026 in Review

Callan Family Office reduced its Zoetis (ZTS) stake by 42% in Q2 2026, selling an estimated $862K and leaving 12,528 shares worth $900K. The position accounts for 0.02% of the portfolio, ranked #625.

Callan Family Office first reported a position in ZTS in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.71M in Q4 2025. 1,435 funds tracked by Wall St. Rank hold ZTS as of Q2 2026.

  • Callan Family Office held 12,528 shares of Zoetis worth $900K as of Q2 2026.
  • Callan Family Office sold 9,157 Zoetis shares in Q2 2026, an estimated $862K.
  • Zoetis made up 0.02% of Callan Family Office's portfolio in Q2 2026, its #625 holding.
  • Callan Family Office first reported a position in Zoetis in Q4 2024 and has held it in 7 quarters since.
  • Callan Family Office's Zoetis position peaked at $2.71M in Q4 2025.
  • 1,435 funds tracked by Wall St. Rank held Zoetis as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.